@article{fa1f2bebd25d4d16a24bf84f215821b7,
title = "Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma",
author = "Connors, {Joseph M.} and Ansell, {Stephen M.} and Michelle Fanale and Park, {Steven I.} and Anas Younes",
note = "Funding Information: Conflict-of-interest disclosure: J.M.C.{\textquoteright}s institution receives support for research from F Hoffmann La Roche; Bristol Myers Squibb; Takeda Pharmaceutical Company; and Seattle Genetics. S.I.P. receives research support from Seattle Genetics and Teva; serves on advisory boards for Cornerstone Pharmaceuticals and Teva; and serves on a speaker{\textquoteright}s bureau for Gilead. S.M.A.{\textquoteright}s institution receives support for research from Takeda Pharmaceutical Company and Seattle Genetics.A.Y.receiveshonorariaforconsultingfromMerck,Bristol MyersSquibb, Bayer, Celgene, Incyte, Sanofi, Janssen R&D, Seattle Genetics, and Takeda Millennium; and research funding from Novartis, Johnson and Johnson, Curis, Roche,andBristol MyersSquibb.M.F.servesinaconsultingroleoronanadvisory board for Bristol Myers Squibb and Merck; receives honoraria from Seattle Genetics and Takeda; and receives research funding from Bristol Myers Squibb, Merck, Takeda, and Seattle Genetics.",
year = "2017",
month = sep,
day = "14",
doi = "10.1182/blood-2017-05-784678",
language = "English (US)",
volume = "130",
pages = "1375--1377",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",
}